Abstract:Aims/hypothesis: In type 1 diabetes, the counterregulatory glucagon response to low plasma glucose is impaired. The resulting increased risk of hypoglycaemia necessitates novel strategies to ameliorate alpha-cell impairment. Here, we aimed to establish an in vitro model of alpha-cell impairment in type 1 diabetes using human islet microtissues (MTs) exposed to proinflammatory cytokines. Additionally, we investigated the therapeutic potential of incretin receptor agonists in improving alpha-cell responses to low glucose. Methods: Human islet MTs were exposed to proinflammatory cytokines (IL-1β, IFN-γ, and TNF-α) for 1 day (short-term) and 6 days (long-term). Alpha-cell function was assessed by sequential glucose-dependent secretion assays at 2.8 and 16.7 mmol/l glucose, followed by glucagon measurements. Additional evaluations included ATP content, caspase-3/7 activity, chemokine secretion, and expression of islet transcription factors and hormones. The effects of incretin receptor agonist treatment (glucose-dependent insulinotropic polypeptide (GIP) analogue [D-Ala ]-GIP ± liraglutide) alongside or after cytokine exposure were also investigated, focusing on low glucose-dependent glucagon secretion. Results: Short-term cytokine exposure increased glucagon secretion at both 2.8 and 16.7 mmol/l glucose. In contrast, long-term cytokine exposure caused dose-dependent suppression of glucagon secretion at 2.8 mmol/l glucose, resembling a type 1 diabetes phenotype. Long-term cytokine exposure also diminished somatostatin secretion, reduced ATP content, increased caspase 3/7 activity, and decreased islet transcription factor and hormone expression. Despite cytokine-induced impairment, alpha cells partially retained secretory capacity to L-arginine stimulation. Treatment with incretin receptor agonists during long-term cytokine exposure did not prevent alpha-cell impairment. However, acute treatment with [D-Ala ]-GIP ± liraglutide or the single-molecule dual agonist tirzepatide partially restored glucagon secretion at low glucose. Conclusions/interpretation: Long-term cytokine exposure of human islet MTs impaired glucagon secretion to low glucose, creating a type 1 diabetes alpha-cell phenotype. This cytokine-induced alpha-cell impairment was partially restored by [D-Ala ]-GIP ± liraglutide and tirzepatide, respectively.

[The role of syntaxin1A/synaptosome-associated protein-25 in reversing hyperglycemia-induced alpha cell toxicity].

Glucotoxicity and Α Cell Dysfunction: Involvement of the PI3K/Akt Pathway in Glucose-Induced Insulin Resistance in Rat Islets and Clonal Αtc1-6 Cells.

Impact of glucotoxicity on TC1-6 cell glucagon secretion

Hyperoxia Reverses Glucotoxicity-Induced Inhibition of Insulin Secretion in Rat INS-1 Β Cells.

Misrouting of glucagon and stathmin-2 towards lysosomal system of α-cells in glucagon hypersecretion of diabetes

The chronic hyperglycemia promotes functional impairment of beta cell of islet by lipotoxicity in rats

Increasing Glucagon Secretion Could Antagonize The Action Of Exogenous Insulin For Glycemic Control In Streptozocin-Induced Diabetic Rhesus Monkeys

Ghrelin Improves Glucolipotoxicity-Induced Pancreatic β-Cellular Dysfunction and Apoptosis by Inhibiting Endoplasmic Reticulum Stress-Induced IRE1/JNK Pathway

Exendin-4 and Liraglutide Attenuate Glucose Toxicity-Induced Cardiac Injury through mTOR/ULK1-Dependent Autophagy.

The changes of Sodium iodide symporter, thyrotropin receptor mRNA and protein expression in thyroid gland of diabetic rats

Proinflammatory cytokine-induced alpha-cell impairment in human islet microtissues is partially restored by dual incretin receptor agonism

Adiponectin Reduces Glucotoxicity-Induced Apoptosis of Ins-1 Rat Insulin-Secreting Cells on A Microfluidic Chip

Experimental Study on the Glucagon-Likepeptide 1 Receptor Agonist Modulation of Insulin Resistance and Hepatic Oxidative Stress in Rats with Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease

Glucagon-Like Skin-1’s Effect on Islet β Cells in High Glucose via AMPK/mTOR Pathway

Liraglutide Inhibits Autophagy and Apoptosis Induced by High Glucose Through GLP-1R in Renal Tubular Epithelial Cells

Alpha Cell Thioredoxin-interacting Protein Deletion Improves Diabetes-associated Hyperglycemia and Hyperglucagonemia

Alanyl-glutamine improves pancreatic β-cell function following ex vivo inflammatory challenge

Therapeutic Effects of GLP-1 Analog on Rats with Experimental Diabetes Mellitus

[Jiangtang Sanhuang tablet inhibits endoplasmic reticulum stress and autophagy in diabetic mouse islet cells]

Protective Effect of Recombinant Human Glucagon‐like Peptide‐1 (rhglp‐1) Pretreatment in STZ‐induced Diabetic Mice

GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity